Expanding the Euro-BioImaging portfolio

Published: 2020-04-22

To remain at the technological forefront, Euro-BioImaging uses “showcasing” and “proof-of-concept” studies to ensure that new technologies are continuously integrated into its portfolio. The first proof-of-concept studies includes Photoacoustic Imaging, Mass Spectrometry Imaging, Coherent anti-Stokes Raman scattering (CARS) microscopy and Quantitative Phase Imaging. These technologies will be offered through the Euro-BioImaging Web Portal for user access once the COVID-19 emergency is under control and Nodes are fully operational. 

Additional technologies that were successfully showcased include: Magnetoencephalography, Correlated Optical Coherence Tomography/Photoacoustic Imaging, Micro X-ray Fluorescence Spectrometry, and Brillouin Light Scattering Microscopy. In the future, new Nodes offering these technologies will be eligible to offer access via the proof-of-concept procedure. In the meantime, Euro-BioImaging welcomes any user, service provider or manufacturer to showcase new technologies for consideration of inclusion into the EuBI portfolio. For more information visit the new technologies page on our Portal:  https://www.eurobioimaging.eu/about-us/new-technologies 

We use cookies to manage and improve the services of the Euro-BioImaging Web Portal. To find out more, read our Privacy policy.
Please note: For best experience we do not recommend using Internet Explorer.